Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Dec 17, 2017
Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors Thomas J. Riga Named Chief Operating Officer Stuart M. Krassner , ScD, PsyD Named Chairman of the Board HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with
Dec 13, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced two oral presentations of data on FOLOTYN and research progress for the
Dec 04, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Nov 08, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals , Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Nov 02, 2017
Poziotinib: Objective Response Rate of 73% was observed in preliminary analysis from an ongoing Phase 2 study conducted by MD Anderson Cancer Center in Non-Small-Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The Company has initiated a multicenter clinical trial to
Oct 30, 2017
The study will evaluate Objective Response Rate (ORR) as the primary endpoint. Objective Response Rate of 73% was observed in preliminary analysis of an ongoing Phase 2 study being conducted by Dr. John Heymach at the University of Texas MD Anderson Cancer Center .
Oct 26, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Oct 17, 2017
Poziotinib demonstrates evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with interim data showing an Objective Response Rate of 73%. Evidence of central nervous system (CNS) activity in a patient with CNS metastasis and another with leptomeningeal
Oct 10, 2017
Approximately $40.5 Million in Principal Amount of Notes Will Be Outstanding Following the Exchanges HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders
Sep 29, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that between August 11, 2017 and September 29, 2017 , it issued an
Sep 28, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the release of an abstract from a clinical study evaluating
Sep 05, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Aug 17, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Aug 14, 2017
Qapzola is a novel drug activated by DT-diaphorase, an enzyme over-expressed in bladder cancer cells, to generate cytotoxic species leading to cell death. NMIBC is the fifth most common cancer in the U.S. with the highest lifetime cost per patient. It is an unmet medical need due to high recurrence
Aug 03, 2017
ROLONTIS™ (eflapegrastim): BLA filing expected next year. Enrollment completed in registrational ADVANCE Study under a Special Protocol Assessment (SPA) with the FDA . Topline results expected in Q1 2018. A second smaller study RECOVER is enrolling patients in EU and U.S.
Aug 01, 2017
Enrollment completed ahead of schedule. The Company plans to announce topline data in Q1 2018 and file a Biologics License Application (BLA) next year. To strengthen the regulatory package for U.S. and EU, the Company is enrolling patients in an additional international Phase 3 study (RECOVER),
Jul 27, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Jun 19, 2017
The FOLOTYN (antifolate) and an HDAC inhibitor (romidepsin) combination was shown to achieve a 71% overall response rate (ORR) among PTCL patients. HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug
Jun 02, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of clinical data for FOLOTYN ® (pralatrexate
May 30, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Displaying 61 - 80 of 784